CR20200445A - Inhibidores de la arginasa - Google Patents

Inhibidores de la arginasa

Info

Publication number
CR20200445A
CR20200445A CR20200445A CR20200445A CR20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A CR 20200445 A CR20200445 A CR 20200445A
Authority
CR
Costa Rica
Prior art keywords
compounds
arginase inhibitors
arg2
arg1
inhibitors
Prior art date
Application number
CR20200445A
Other languages
English (en)
Inventor
Eric Thomas Newcomb
Corinne Nicole Foley
Rebecca Louise Grange
Jaroslaw Kalisiak
Anh Thu Tran
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of CR20200445A publication Critical patent/CR20200445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>En el presente documento se describen compuestos que son inhibidores de al menos uno de ARG1 y ARG2 y composiciones que contienen los compuestos y métodos para sintetizar los compuestos. En el presente documento también se describe el uso de tales compuestos y composiciones para el tratamiento de una diversidad de enfermedades, trastornos y afecciones, incluidos los trastornos relacionados con el cáncer y con el sistema inmunitario que están mediados, al menos en parte, por ARG1 y ARG2.</p>
CR20200445A 2018-03-05 2019-03-04 Inhibidores de la arginasa CR20200445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862638412P 2018-03-05 2018-03-05
PCT/US2019/020507 WO2019173188A1 (en) 2018-03-05 2019-03-04 Arginase inhibitors

Publications (1)

Publication Number Publication Date
CR20200445A true CR20200445A (es) 2021-04-27

Family

ID=67847429

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200445A CR20200445A (es) 2018-03-05 2019-03-04 Inhibidores de la arginasa

Country Status (21)

Country Link
US (1) US12054500B2 (es)
EP (1) EP3761992A4 (es)
JP (1) JP7402167B2 (es)
KR (1) KR102656571B1 (es)
CN (1) CN111818928A (es)
AU (1) AU2019229978B2 (es)
BR (1) BR112020017604A2 (es)
CA (1) CA3091805A1 (es)
CL (1) CL2020002271A1 (es)
CO (1) CO2020012060A2 (es)
CR (1) CR20200445A (es)
EA (1) EA202092086A1 (es)
IL (1) IL276813B2 (es)
MX (1) MX2020009290A (es)
MY (1) MY205512A (es)
PE (1) PE20210452A1 (es)
PH (1) PH12020551352A1 (es)
SG (1) SG11202008113RA (es)
UA (1) UA127897C2 (es)
WO (1) WO2019173188A1 (es)
ZA (1) ZA202006006B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AU2022376961A1 (en) 2021-10-29 2024-05-16 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
US20250179176A1 (en) 2022-05-02 2025-06-05 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
KR20250065402A (ko) 2022-09-14 2025-05-12 아르커스 바이오사이언시즈 인코포레이티드 에트루마데난트 분산체
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
TW202428286A (zh) 2022-10-20 2024-07-16 美商阿克思生物科學有限公司 Ｃｄ７３化合物之凍乾配方
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
JP4109123B2 (ja) 2001-05-09 2008-07-02 セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド ペプチドデホルミラーゼ活性化プロドラッグ
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2371514T3 (es) 2007-07-03 2012-01-04 Actelion Pharmaceuticals Ltd. Compuestos de 3-aza-biciclo[3.3.0]octano.
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
DK2730581T3 (en) 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NZ592507A (en) 2008-11-26 2013-08-30 Abbvie Inc Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
EP2376072A1 (en) 2008-12-29 2011-10-19 Tartu Ülikool (University Of Tartu) Arginase inhibitors for the treatment of depression
HRP20191433T1 (hr) 2009-01-26 2019-11-15 Univ Pennsylvania Inhibitori arginaze i metode primjene
RU2595409C2 (ru) 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Анти-gitr-антитела
AU2010329934B2 (en) 2009-12-10 2015-05-14 F. Hoffmann-La Roche Ag Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
MX355418B (es) 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
DK2632927T3 (en) * 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
EP2812355A4 (en) 2012-02-06 2016-03-02 Hoffmann La Roche COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013249790B2 (en) 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EA201690007A1 (ru) 2013-06-12 2016-04-29 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EP3131400A4 (en) 2014-04-15 2017-11-29 Dow AgroSciences LLC Metalloenzyme inhibitor compounds as fungicides
CL2014002403A1 (es) 2014-09-11 2015-01-09 Univ Pontificia Catolica Chile Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion.
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
WO2016100555A1 (en) * 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2019232704B2 (en) 2018-03-05 2024-03-21 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11274111B2 (en) * 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use

Also Published As

Publication number Publication date
JP2021516237A (ja) 2021-07-01
UA127897C2 (uk) 2024-02-07
PE20210452A1 (es) 2021-03-08
PH12020551352A1 (en) 2021-06-21
US20210002306A1 (en) 2021-01-07
BR112020017604A2 (pt) 2020-12-22
CL2020002271A1 (es) 2021-04-09
KR102656571B1 (ko) 2024-04-11
CN111818928A (zh) 2020-10-23
IL276813A (en) 2020-10-29
SG11202008113RA (en) 2020-09-29
AU2019229978A1 (en) 2020-10-15
AU2019229978B2 (en) 2024-05-30
CA3091805A1 (en) 2019-09-12
MX2020009290A (es) 2020-09-28
MY205512A (en) 2024-10-24
CO2020012060A2 (es) 2021-01-18
EP3761992A1 (en) 2021-01-13
EA202092086A1 (ru) 2021-02-09
ZA202006006B (en) 2025-02-26
IL276813B1 (en) 2024-05-01
IL276813B2 (en) 2024-09-01
WO2019173188A1 (en) 2019-09-12
EP3761992A4 (en) 2021-11-24
JP7402167B2 (ja) 2023-12-20
KR20200128117A (ko) 2020-11-11
US12054500B2 (en) 2024-08-06

Similar Documents

Publication Publication Date Title
ZA202006006B (en) Arginase inhibitors
WO2020102646A3 (en) Inhibitors of arg1 and/or arg2
CR20220470A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
PH12021500030A1 (en) Il-2 conjugates and methods of use thereof
NZ754731A (en) Azolopyrimidine for the treatment of cancer-related disorders
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
PH12022500003A1 (en) Il-2 conjugates and methods of use to treat autoimmune diseases
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
EP4292662A3 (en) Substituted indole mcl-1 inhibitors
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
WO2021022163A3 (en) Compounds and uses thereof
PH12023552079A1 (en) Cdk2 inhibitors and methods of using the same
MX2022000712A (es) Moduladores de nlrp3.
AU2018320418A1 (en) Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
EP4663247A3 (en) Formulations/compositions comprising a btk inhibitor
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
MX2021013602A (es) Inhibidores de jak.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.